Literature DB >> 29332563

Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.

Matheus de Freitas Silva1, Kris Simone Tranches Dias1, Vanessa Silva Gontijo1, Cindy Juliet Cristancho Ortiz1, Claudio Viegas1.   

Abstract

Alzheimer's disease (AD) is a progressive multifactorial neurodegenerative disorder. Currently, no effective treatment is available and this is due to multiple factors involved in pathophysiology and severity of AD. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDL) strategy, has been used to develop a variety of hybrid compounds capable to act simultaneously in diverse biological targets. The discovery of drug candidates capable of targeting multiple factors involved in AD pathogenesis would greatly facilitate in improving therapeutic strategies. This review is a complement to another review article, recently published by our group, which covered the previous period of 2005-2012, and highlights recent advances and examples of the exploitation of MTDLs approach in the rational design of novel drug candidate prototypes for the treatment of AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer`s disease; MTDLs; multi-target directed drugs; multifunctional drugs; multitargetzzm321990drugs; neurodegenerative diseases; rational drug design.

Mesh:

Substances:

Year:  2018        PMID: 29332563     DOI: 10.2174/0929867325666180111101843

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  13 in total

1.  Safranal protects against beta-amyloid peptide-induced cell toxicity in PC12 cells via MAPK and PI3 K pathways.

Authors:  Faezeh Rafieipour; Elham Hadipour; Seyed Ahmad Emami; Javad Asili; Zahra Tayarani-Najaran
Journal:  Metab Brain Dis       Date:  2018-11-06       Impact factor: 3.584

2.  Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation.

Authors:  Cheng-Shi Jiang; Yong-Xi Ge; Zhi-Qiang Cheng; Jia-Li Song; Yin-Yin Wang; Kongkai Zhu; Hua Zhang
Journal:  J Comput Aided Mol Des       Date:  2019-04-15       Impact factor: 3.686

3.  Design, synthesis, and biological evaluation of new thalidomide-donepezil hybrids as neuroprotective agents targeting cholinesterases and neuroinflammation.

Authors:  Cindy Juliet Cristancho Ortiz; Matheus de Freitas Silva; Letizia Pruccoli; Nathália Fonseca Nadur; Luciana Luíza de Azevedo; Arthur Eugen Kümmerle; Isabella Alvim Guedes; Laurent Emmanuel Dardenne; Luiz Felipe Leomil Coelho; Marcos J Guimarães; Fernanda M R da Silva; Newton Castro; Vanessa Silva Gontijo; Viviana C T Rojas; Merelym Ketterym de Oliveira; Fabiana Cardoso Vilela; Alexandre Giusti-Paiva; Gisele Barbosa; Lídia Moreira Lima; Gabriela Beserra Pinheiro; Letícia Germino Veras; Márcia Renata Mortari; Andrea Tarozzi; Claudio Viegas
Journal:  RSC Med Chem       Date:  2022-03-17

4.  Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities.

Authors:  Leili Jalili-Baleh; Hamid Nadri; Hamid Forootanfar; Tuba Tüylü Küçükkılınç; Beyza Ayazgök; Mohammad Sharifzadeh; Mahban Rahimifard; Maryam Baeeri; Mohammad Abdollahi; Alireza Foroumadi; Mehdi Khoobi
Journal:  Daru       Date:  2021-01-09       Impact factor: 3.117

Review 5.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

6.  Co-Immobilized Capillary Enzyme Reactor Based on Beta-Secretase1 and Acetylcholinesterase: A Model for Dual-Ligand Screening.

Authors:  Adriana Ferreira Lopes Vilela; Vitor Eduardo Narciso Dos Reis; Carmen Lúcia Cardoso
Journal:  Front Chem       Date:  2021-07-08       Impact factor: 5.221

7.  Dreaming of a New World Where Alzheimer's Is a Treatable Disorder.

Authors:  Marcella Catania; Giorgio Giaccone; Mario Salmona; Fabrizio Tagliavini; Giuseppe Di Fede
Journal:  Front Aging Neurosci       Date:  2019-11-15       Impact factor: 5.750

8.  Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations.

Authors:  Rani Sasidharan; Bo Hyun Eom; Jeong Hyun Heo; Jong Eun Park; Mohamed A Abdelgawad; Arafa Musa; Nicola Gambacorta; Orazio Nicolotti; Sreedharannair Leelabaiamma Manju; Bijo Mathew; Hoon Kim
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

9.  New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer's Disease Treatment.

Authors:  Galina F Makhaeva; Nadezhda V Kovaleva; Natalia P Boltneva; Sofya V Lushchekina; Tatiana Yu Astakhova; Elena V Rudakova; Alexey N Proshin; Igor V Serkov; Eugene V Radchenko; Vladimir A Palyulin; Sergey O Bachurin; Rudy J Richardson
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

Review 10.  Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents.

Authors:  Elisabete Lima; Jorge Medeiros
Journal:  Mar Drugs       Date:  2022-01-15       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.